Results showed a greater percentage of povorcitinib-treated patients achieved HiSCR50 compared with placebo at week 12. Topline data were announced from two pivotal phase 3 studies evaluating ...

Please provide your email address to receive an email when new articles are posted on . The newly presented data is from the two STOP-HS trials, both of which met their primary endpoints.

In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click here to read why INCY is a Buy.

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Incyte unveiled positive top-line results from a pair of late-stage studies of its povorcitinib drug candidate in the chronic, inflammatory skin condition hidradenitis suppurativa. Incyte on ...

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials evaluating povorcitinib, an oral JAK1 inhibitor, for moderate to severe ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

- Incyte to hold an analyst and investor call on Monday, March 17, 2025 from 8:00-9:00 a.m. ET Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS ...

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

- Incyte to hold an analyst and investor call on Monday, March 17, 2025 from 8:00-9:00 a.m. ET WILMINGTON, Del., March 17, 2025--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced positive ...